FDA approves ‘game-changing’ pancreatic cancer drug
Categories: health
Quick Summary
The FDA has approved a new drug called Daraxonrasib, also known as Rasonque, for the treatment of pancreatic cancer. This oral medication targets a specific mutation in the KRAS gene, which is commonly found in pancreatic cancer patients, and has shown efficacy in a clinical trial. The approval provides a new treatment option for patients with this mutation, and the drug is expected to be available in the coming weeks.
Key Points
- The FDA has approved a new drug called Daraxonrasib, also known as Rasonque, for the treatment of pancreatic cancer.
- Daraxonrasib is an oral medication that targets a specific mutation in the KRAS gene, which is commonly found in pancreatic cancer patients.
- The approval is based on a clinical trial that showed the drug's efficacy in treating patients with the KRAS G12C mutation.
- The drug's manufacturer, Rain Therapeutics, plans to make Daraxonrasib available to patients in the coming weeks.
View Original Article
This summary is AI generated and may be inaccurate